ClinicalTrials.gg
RecruitingNCT07673562DEPIST'IC-RUNUpdated Sep 23, 2026

The Value of a Simple Tool for the Early Detection of Decompensated Heart Failure in People Over 55 on Réunion Island: A Preliminary Study in Hospitals (DEPIST'IC-RUN)

An observational study in Heart Failure, sponsored by Centre Hospitalier Universitaire de la Réunion. Recruiting at 3 sites in Reunion. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Centre Hospitalier Universitaire de la Réunion · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
55 Years and older
Sex
All
01

Study summary

The goal of this study is to assess the discriminatory power of a previously developed tool for detecting decompensated heart failure-which includes, in particular, clinical signs-in a population of patients hospitalized in cardiology units in Réunion. The main question it aims to answer is : Would a simple and rapid screening tool for decompensated heart failure help identify a high probability of this condition in a population hospitalized in a cardiology unit in Réunion? This study includes patients aged 55 and older, who reside in Réunion, who were admitted on an unscheduled basis to the cardiology department at the Réunion University Hospital or the Ouest Réunion Hospital, for any reason (whether as an inpatient or in the intensive care unit)

The study is conducted in two phases:

Phase 1: Development of the new e-DELPHI consensus-based screening tool Phase 2: Administration of the Déspist'IC-Run early detection tool for decompensated heart failure and performance of the gold standard cardiology examination (RIPH3)

Read the detailed description

This is a preliminary, cross-sectional "diagnostic" ("screening") study (to assess validity relative to the gold standard test), conducted at two centers, evaluating a questionnaire that does not alter the patient's standard of care (prospective data collection).

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Decompensated heart failure
  • early detection
  • questionnaire
03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's planned enrollment of 300 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 141 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 55 or older who reside on Réunion Island and are hospitalized in the cardiology department of the University Hospital (CHU) or the Centre Hospitalier Ouest Réunion (CHOR)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients:

  • Aged 55 and older
  • Admitted on an unscheduled basis to the cardiology department at the CHU (North and South campuses) and the CHOR for any reason (in general wards or intensive care)
  • Residents of Réunion
  • Able to read and write French
  • Enrolled in a social security program
  • Willing to participate in the study

Exclusion criteria

Exclusion Criteria:

Patients:

  • Who cannot communicate in French
  • For whom it is impossible to administer the questionnaire
  • For whom the ETT and/or cardiology consultation are impossible
  • Who are under guardianship, conservatorship, or judicial protection
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cardiology patients

    Patients aged 55 or older admitted to a cardiology unit for any reason

    Diagnostic Test: Early Detection Questionnaire

Interventions

  • Diagnostic testEarly Detection Questionnaire

    Questionnaire for the Early Detection of Heart Failure

06

What researchers measure

Primary outcomes

  1. Estimating the discriminant validity of a tool for detecting decompensated heart failure

    The probability of having decompensated heart failure, as determined by a screening tool in the form of a questionnaire, will be calculated using the equation of a logistic regression model that explains the observed status (dependent variable) as determined by the gold standard test. The gold standard test for establishing a definitive diagnosis of decompensated heart failure will combine three tests: a clinical examination by a cardiologist, a transthoracic Doppler echocardiogram (TTE), and an electrocardiogram.

    Time frame: "From enrollment to the end of the study, at 6 month

Secondary outcomes

  1. Describe the operational phases involved in developing the screening tool.

    The detailed description of the tool's development phase is a task that complements statistical modeling (of the tool's development) and is purely epidemiological in nature.

    Time frame: From enrolment to the end of the study, at 6 month

  2. Describe the sociodemographic and clinical characteristics, as well as the lifestyle habits, of the study population.

    The following characteristics are collected: age, sex, socioeconomic status, residential area (north, south, west, east); cardiovascular risk factors (hypertension, diabetes, dyslipidemia, known heart disease, history of myocardial infarction, end-stage renal disease requiring dialysis); lifestyle factors (Body Mass Index (kg/m²), physical activity \> 30 min at least 3 times/week, current smoking, alcohol consumption \> 3 drinks/day).

    Time frame: From enrollment to the end of the study at 6 months

  3. Compare the sociodemographic and medical characteristics of this population of patients hospitalized in cardiology with those of other populations of patients with heart failure seen in private practices-whether in cardiology or general practice

    Socio-demographic data (age, sex, residential area) and clinical data (cardiovascular history) for the population with heart failure in Réunion, obtained from the SNDS, will be compared with those of the sample in this study

    Time frame: From enrollment to the end of the study at 6 month

07

Study locations

1 of 3 sites recruiting
  • CHU Réunion - NORD
    Saint-Denis, Reunion 97400, Reunion
    Recruiting
  • CHOR
    Saint-Paul, Reunion 97460, Reunion
    Not yet recruiting
  • CHU Réunion- SUD
    Saint-Pierre, Reunion 97448, Reunion
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 793 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 6 months is below that.

Counting every sponsor, half of 975 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 29, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07673562
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Aug 1, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Jérôme CORRE, Dr
Contact
jerome.corre@chu-reunion.fr
+262 262 90 05 52

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion